Type ? Target CD19 ChemSpider none | Source Humanized (from mouse) ATC code none | |
SGN-CD19A is an antibody-drug conjugate (ADC) directed to CD19 designed for the treatment of CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. It consists of an anti-CD19 mAb linked to monomethyl auristatin F (MMAF), a cytotoxic agent.
Contents
Also known as Denintuzumab mafodotin Denintuzumab refers to the anti-CD19 antibody, and mafodotin refers to MMAF and the chemical linkage.
Clinical trials
The drug is currently in phase I clinical trials. Preliminary phase I results for B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) and B-lineage acute lymphocytic leukemia (B-ALL) are being presented at the ASH medical conference Dec 2015.
Phase 2
A separate randomized phase 2 trial has started in 2015 to evaluate SGN-CD19A in combination with R-ICE chemotherapy for second-line DLBCL.
A phase 2 clinical trial in front-line DLBCL is due to start in 2016.